Article ; Online: The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder.
Journal of affective disorders
2022 Volume 315, Page(s) 13–16
Abstract: Background: Comorbid borderline personality disorder and major depressive disorder is common and often not adequately responsive to standard antidepressant therapies. Ketamine is a potentially life-saving option.: Methods: 153 adult patients with MDD ...
Abstract | Background: Comorbid borderline personality disorder and major depressive disorder is common and often not adequately responsive to standard antidepressant therapies. Ketamine is a potentially life-saving option. Methods: 153 adult patients with MDD were assessed with the Personality Assessment Inventory (PAI) Borderline Subscale. Data was normally distributed with a mean + SD of 38.95 + 11.54. Patients >1 SD above the mean were assigned to the MDD + BF group. All others were assigned to the MDD-BF group. Patients were administered IV ketamine 0.5 mg/kg of ketamine over 40 min. Mood was assessed using the Beck Depression Inventory-II at baseline, 3 and 24 h post-ketamine. Scores between the MDD + BF and MDD-BF group at each time point were compared using t-test or analysis of covariance (ANCOVA) model. The primary outcome was response at 24 h. Results: The LS mean change in BDI at 24 h was -23.8 (15.3) for MDD + BF and -21.0 (13.5) for MDD-BF (F [1151] = 0.043, p = 0.51). The LS mean change in BDI at 3 h was -21.3 (13.2) for MDD + BF and -19.6 (13.2) for MDD-BF (F[1151] = 0.045, p = 0.83). The LS mean change in BDI at 14 days was -23.2 (15.3) for MDD + BF and -15.3 (15.2) for MDD-BF (F[1130] = 4.24, p = 0.04). Limitations: People in the MDD + BF group were not necessarily diagnosable with borderline personality disorder. Conclusions: These data indicate that IV ketamine is effective in MDD patients with and without elevated borderline features. This can provide clinicians some reassurance about using ketamine in this population. |
---|---|
MeSH term(s) | Adult ; Antidepressive Agents/therapeutic use ; Borderline Personality Disorder/drug therapy ; Borderline Personality Disorder/epidemiology ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Major/epidemiology ; Humans ; Ketamine/therapeutic use ; Personality Assessment |
Chemical Substances | Antidepressive Agents ; Ketamine (690G0D6V8H) |
Language | English |
Publishing date | 2022-07-26 |
Publishing country | Netherlands |
Document type | Journal Article ; Research Support, N.I.H., Extramural |
ZDB-ID | 135449-8 |
ISSN | 1573-2517 ; 0165-0327 |
ISSN (online) | 1573-2517 |
ISSN | 0165-0327 |
DOI | 10.1016/j.jad.2022.07.054 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1485: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.